PapersFlow Research Brief
Platelet Disorders and Treatments
Research Guide
What is Platelet Disorders and Treatments?
Platelet disorders and treatments encompass medical conditions characterized by abnormal platelet function, number, or activity—such as immune thrombocytopenic purpura (ITP) and von Willebrand disease—along with therapeutic interventions targeting hemostasis, thrombosis, and related mechanisms including platelet aggregation and thrombus formation.
This field includes 74,587 papers on platelet disorders, thrombosis mechanisms, and conditions like immune thrombocytopenic purpura and von Willebrand disease. Topics cover platelet function, hemostasis, inflammation, megakaryocyte development, and molecular mechanisms of thrombus formation. Growth rate over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Immune Thrombocytopenic Purpura Pathophysiology
This sub-topic investigates autoantibody-mediated platelet destruction and impaired megakaryopoiesis in ITP. Researchers study FcγR polymorphisms and T-cell dysregulation using cohort and animal models.
von Willebrand Disease Molecular Genetics
This sub-topic classifies VWD types via VWF gene mutations and multimer analysis. Researchers correlate genotypes with bleeding phenotypes and ABO influences.
Platelet Glycoprotein Ib-IX-V Function
This sub-topic examines GPIbα-vWF adhesion under shear and signaling via 14-3-3ζ. Researchers use flow chamber assays and Bernard-Soulier syndrome models.
Megakaryocyte Development and Thrombopoiesis
This sub-topic studies TPO signaling, polyploidization, and proplatelet formation. Researchers employ iPSC-derived models and knockout mice.
Neutrophil Extracellular Traps in Thrombosis
This sub-topic investigates NETosis promotion of thrombus stability via DNA-histone networks. Researchers test PAD4 inhibitors in venous thrombosis models.
Why It Matters
Platelet disorders and treatments address critical hematological issues affecting hemostasis and thrombosis, with direct applications in managing bleeding and clotting risks. Desmopressin (DDAVP) has treated children with von Willebrand disease and Hemophilia A for nearly 35 years, reducing exposure to human plasma-derived products while maintaining a good safety profile, as noted in "Hematological Problems in Pediatric Intensive Care" by Revel‐Vilk et al. (2013). Standardization efforts, such as those in "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" by Rodeghiero et al. (2008), enable reliable clinical trials and meta-analyses for ITP management. "Extracellular DNA traps promote thrombosis" by Fuchs et al. (2010) demonstrates how neutrophil extracellular traps (NETs) contribute to thrombus formation, informing therapies for thrombosis-related disorders.
Reading Guide
Where to Start
"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" by Rodeghiero et al. (2008) is the best starting paper, as it provides foundational definitions and criteria essential for understanding ITP diagnosis and management.
Key Papers Explained
"Integrins: Versatility, modulation, and signaling in cell adhesion" by Hynes (1992) establishes integrin roles in cell adhesion relevant to platelets. "Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal" by Born (1962) builds on this by detailing ADP-mediated aggregation mechanisms. "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" by Rodeghiero et al. (2008) applies these to clinical ITP contexts. "Extracellular DNA traps promote thrombosis" by Fuchs et al. (2010) extends to NETs' prothrombotic effects involving platelets.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on molecular thrombus formation mechanisms, as in "Extracellular DNA traps promote thrombosis" by Fuchs et al. (2010), and pediatric applications like desmopressin in von Willebrand disease from "Hematological Problems in Pediatric Intensive Care" by Revel‐Vilk et al. (2013). No recent preprints or news coverage indicate steady progress without major shifts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Integrins: Versatility, modulation, and signaling in cell adhe... | 1992 | Cell | 9.9K | ✕ |
| 2 | International consensus statement on an update of the classifi... | 2006 | Journal of Thrombosis ... | 7.0K | ✓ |
| 3 | Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mi... | 1989 | Science | 5.0K | ✕ |
| 4 | Aggregation of Blood Platelets by Adenosine Diphosphate and it... | 1962 | Nature | 4.3K | ✕ |
| 5 | Hematological Problems in Pediatric Intensive Care | 2013 | Pediatric and adolesce... | 3.5K | ✕ |
| 6 | Requirement of Vascular Integrin α <sub>v</sub> β <sub>3</sub>... | 1994 | Science | 3.0K | ✕ |
| 7 | Leukocyte-endothelial cell recognition: Three (or more) steps ... | 1991 | Cell | 2.8K | ✕ |
| 8 | Standardization of terminology, definitions and outcome criter... | 2008 | Blood | 2.6K | ✓ |
| 9 | Lymphocyte egress from thymus and peripheral lymphoid organs i... | 2004 | Nature | 2.5K | ✕ |
| 10 | Extracellular DNA traps promote thrombosis | 2010 | Proceedings of the Nat... | 2.3K | ✓ |
Frequently Asked Questions
What are the classification criteria for antiphospholipid syndrome?
"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)" by Miyakis et al. (2006) provides updated criteria for definite APS diagnosis. These criteria standardize identification of this condition linked to thrombosis and platelet-related complications. They facilitate consistent clinical and research applications.
How does desmopressin treat platelet disorders in children?
Desmopressin (DDAVP) treats von Willebrand disease and Hemophilia A in children, as described in "Hematological Problems in Pediatric Intensive Care" by Revel‐Vilk et al. (2013). It has been used for almost 35 years, substantially lowering exposure to human plasma-derived products. The treatment maintains a good safety profile.
What role do neutrophil extracellular traps play in thrombosis?
Neutrophil extracellular traps (NETs) promote thrombosis, according to "Extracellular DNA traps promote thrombosis" by Fuchs et al. (2010). NETs form a meshwork of DNA fibers with histones and antimicrobial proteins that immobilize microbes but also contribute to clot formation. This mechanism links innate immunity to thrombotic disorders.
What standardized terminology exists for immune thrombocytopenic purpura?
"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" by Rodeghiero et al. (2008) establishes terms, definitions, and outcomes for ITP in adults and children. This addresses obstacles in clinical trials and meta-analyses due to prior variability. Standardized criteria improve diagnosis and management reliability.
How do integrins contribute to platelet-related processes?
"Integrins: Versatility, modulation, and signaling in cell adhesion" by Hynes (1992) details integrins' roles in cell adhesion, including platelet function. These receptors modulate signaling relevant to hemostasis and thrombosis. The paper highlights their versatility in vascular biology.
What triggers blood platelet aggregation?
"Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal" by Born (1962) shows adenosine diphosphate induces platelet aggregation. This process is reversible, providing insights into hemostasis mechanisms. The findings underpin studies on thrombus formation.
Open Research Questions
- ? How do neutrophil extracellular traps (NETs) specifically interact with platelets to initiate thrombus formation?
- ? What molecular pathways link integrin signaling to megakaryocyte development in immune thrombocytopenic purpura?
- ? Can standardized ITP criteria predict treatment responses across diverse patient populations?
- ? What are the long-term impacts of desmopressin on von Willebrand disease progression in pediatric cases?
- ? How do S1P receptor pathways influence platelet egress and inflammation in thrombotic disorders?
Recent Trends
The field maintains 74,587 papers with no specified 5-year growth rate.
Recent emphasis appears in clinical standardization, as in "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group" by Rodeghiero et al. , and pediatric treatments in "Hematological Problems in Pediatric Intensive Care" by Revel‐Vilk et al. (2013).
2008No preprints or news from the last 6-12 months are available.
Research Platelet Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Platelet Disorders and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers